Effect of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure in patients with type-2 diabetes and hypertension: an updated meta-analysis.
SGLT2 inhibitors
Sodium-glucose cotransporter 2 inhibitors
ambulatory blood pressure
hypertension
inflammation
type 2 diabetes mellitus
Journal
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
ISSN: 1530-891X
Titre abrégé: Endocr Pract
Pays: United States
ID NLM: 9607439
Informations de publication
Date de publication:
12 Mar 2024
12 Mar 2024
Historique:
received:
26
09
2023
revised:
28
02
2024
accepted:
01
03
2024
medline:
15
3
2024
pubmed:
15
3
2024
entrez:
14
3
2024
Statut:
aheadofprint
Résumé
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed for type 2 diabetes treatment, have shown potential benefits beyond glycemic control, including a positive impact on blood pressure. This meta-analysis aims to evaluate their effects on patients with type 2 diabetes and hypertension. We searched PubMed, Google Scholar, and Cochrane databases for relevant randomized controlled trials (RCTs) published until May 31, 2023. Ten RCTs involving participants with confirmed Type 2 diabetes mellitus were selected. The intervention group received SGLT2 inhibitors, while the control group received a placebo or standard care. Primary outcomes were 24-hour ambulatory systolic and diastolic blood pressures. The results showed a significant reduction in 24-hour ambulatory systolic blood pressure (WMD = -5.08 mmHg, 95% CI: -7.02 to -3.14, p <0.00001) and diastolic blood pressure (WMD = -2.73 mmHg, 95% CI: -4.25 to -1.20, p = 0.0005) with the use of SGLT2 inhibitors compared to placebo. However, high heterogeneity was observed in both analyses (systolic blood pressure: I In conclusion, this meta-analysis proves that SGLT2 inhibitors significantly reduce 24-hour ambulatory blood pressure. SGLT2 inhibitors may be considered an effective treatment option for lowering blood pressure in addition to standard care in hypertensive patients with type 2 diabetes mellitus.
Sections du résumé
BACKGROUND
BACKGROUND
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed for type 2 diabetes treatment, have shown potential benefits beyond glycemic control, including a positive impact on blood pressure. This meta-analysis aims to evaluate their effects on patients with type 2 diabetes and hypertension.
METHODS
METHODS
We searched PubMed, Google Scholar, and Cochrane databases for relevant randomized controlled trials (RCTs) published until May 31, 2023. Ten RCTs involving participants with confirmed Type 2 diabetes mellitus were selected. The intervention group received SGLT2 inhibitors, while the control group received a placebo or standard care. Primary outcomes were 24-hour ambulatory systolic and diastolic blood pressures.
RESULTS
RESULTS
The results showed a significant reduction in 24-hour ambulatory systolic blood pressure (WMD = -5.08 mmHg, 95% CI: -7.02 to -3.14, p <0.00001) and diastolic blood pressure (WMD = -2.73 mmHg, 95% CI: -4.25 to -1.20, p = 0.0005) with the use of SGLT2 inhibitors compared to placebo. However, high heterogeneity was observed in both analyses (systolic blood pressure: I
CONCLUSION
CONCLUSIONS
In conclusion, this meta-analysis proves that SGLT2 inhibitors significantly reduce 24-hour ambulatory blood pressure. SGLT2 inhibitors may be considered an effective treatment option for lowering blood pressure in addition to standard care in hypertensive patients with type 2 diabetes mellitus.
Identifiants
pubmed: 38484937
pii: S1530-891X(24)00079-X
doi: 10.1016/j.eprac.2024.03.001
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024. Published by Elsevier Inc.